Blirt   company overview
Upcoming SlideShare
Loading in...5
×
 

Blirt company overview

on

  • 405 views

our company

our company

Statistics

Views

Total Views
405
Views on SlideShare
405
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Blirt   company overview Blirt company overview Presentation Transcript

  • A flexible, affordable and fast R&D outsourcing servicepartner
  • Company overview BLIRT (BioLab Innovative Research Technologies) is a private biotechnology company founded in 2008 with head office based in Gdansk, Poland. BLIRT has a unique hybrid model, an innovative biopharmaceutical service provider with Contract Research Organization. BLIRT offers a suite of biology and chemistry services, attractive especially for discovery and lead optimization development phase.  BLIRT has modern laboratories and competent staff with a high percentage of internationally educated PhDs. We are able to accommodate small and bigger projects, and can engage project resources on long term contract or as-needed basis. www.blirt.eu 2
  • Research Team  891 publications in the field of life science ( Medicine, Microbiology, Molecular Biology, Biotechnology, Biochemistry, Organic Chemistry, Analytical Chemistry, Molecular Modeling) BLIRT employes 34 people after 2 years activity. The Research Team consists of 22 researchers where 9 are PhDs at molecular biology, biotechnology, organic chemistry and computer chemistry. www.blirt.eu 3
  • Our machinery www.blirt.eu 4
  • Protein Department We offer a broad spectrum of custom services from gene to protein helping you to speed up your development and to increase the efficiency. Gene Production Purification ProteinIn silico gene synthesis Proof of concept Downstream Processing Formulation Adjustment Metagenomics Difficult to express Optimization proteins solutions Analytical testing PCR Chromatography methods E.coli, P.pastoris, development and validationDNA and cDNA library B. megaterium, S.cerevisiae construction Unique resin synthesis Flask and Bioreactor (10L) for special proteins Gene engineering expression optimizations www.blirt.eu
  • Protein Department Choosing the right expression strain of E.coli Expression T7 system: OD600=0,3, IPTG to 1 2 3 4 5 6 M 7 8 9 10 11 12 1mM, 30oC, 6h, TB broth. 1. E.coli strain 1 protein I (whole fraction) 2. E.coli strain 1 protein I (soluble fraction) 3. E.coli strain 2 protein I (whole fraction) 4. E.coli strain 2 protein I (soluble fraction) 5. E.coli strain 3 protein I (whole fraction) 6. E.coli strain 3 protein I (soluble fraction) M. Protein weight marker (170, 130, 100, 70, 55, 40, 35, 25, 15, 10 kDa) 7. E.coli strain 4 protein I (whole fraction) 8. E.coli strain 4 protein I (soluble fraction) 9. E.coli strain 5 protein I (whole fraction) 10. E.coli strain 5 protein I (soluble fraction) 11. E.coli strain 6 protein I (whole fraction) 12. E.coli strain 6 protein I (soluble fraction) www.blirt.eu 6
  • Protein Department Screening for expression temperature Purification M 1 2 3 4 M 1 2 3 4 5 5 6Expression T7 system: OD600=0,3, IPTG to 1mM, various oC, 6 h, TB broth. Expression T7 system: OD600=0,3, IPTG to 1mM, 37 oC, 6 h, TB broth.M. Protein weight marker (170, 130, 100, 70, 55, 40, 35, 25, 15, 10 kDa) M. Protein weight marker (130, 90, 66, 40, 25, 10 kDa)1. 18oC E.coli strain 1 protein II (whole fraction) 1. E.coli strain 2 protein III (soluble fraction)2. 18oC E.coli strain 1 protein II (soluble fraction) 2. E.coli strain 2 protein III DEAE Sepharose week anion exchanger3. 30oC E.coli strain 1 protein II (whole fraction) 3. E.coli strain 2 protein III Mono Q strong anion exchanger4. 30oC E.coli strain 1 protein II (soluble fraction) 4. E.coli strain 2 protein III Octyl Sepharose HIC5. 37oC E.coli strain 1 protein II (whole fraction) 5. Formulated protein III6. 37oC E.coli strain 1 protein II (soluble fraction) www.blirt.eu 7
  • Protein Department1 2 M 4 5 6 7 8 9 10 11 12 13 14 15 Intracellular production of a therapeutic protein by E.coli. Soluble protein Loading buffer at various pH. Elution stepwise with 50mM Hepes 1M NaCl pH=7,0 DEAE Sepharose 1. pH=4,5 2. pH=5,5 M. Protein weight marker (170, 130, 100, 70, 55, 40, 35, 25, 15, 10 kDa) 4. pH=6,5 Loading buffer containing Triton X- 5. pH=7,5 100 (R) as additive at various pH. 6. pH=8,5 Elution stepwise with 50mM Hepes 7. pH=9,5 1M NaCl pH=7,0 8. pH=10,5 CM Sepharose 9. pH=4,5 10. pH=5,5 11. pH=6,5 Loading buffer containing L- 12. pH=7,5 Arginine as additive at various pH. 13. pH=8,5 Elution stepwise with 50mM Hepes 14. pH=9,5 1M NaCl pH=7,0 15. pH=10,5 www.blirt.eu 8
  • Analysis departmentBLIRT specializes in development of new methods and analyses that are notpossible in diagnostics laboratories. We are also able to conduct all routinetests, particularly those that require our unique equipment.Example analyses that we are able to perform:• Analysis of drugs and its metabolites concentration in blood, urine, other biological fluids andtissues,• Pharmacokinetic analysis after drug administration,• ADME studies – complex analysis of absorption, distribution, metabolism and excretion,• Analysis of purity, stability and protein binding of pharmaceuticals,• Analysis of biochemical markers in blood, urine, other biological fluids and tissues,• Determination of molecular weight and purity of proteins and peptides,• Protein and peptide sequencing following partial proteolysis. www.blirt.eu 9
  • Analysis departmentBLIRT can provide you access to most advanced analytical equipment and highprofile scientists with many years of experience in biomedical analytics.Overview of Analytical Methods:Ultra-High Performance Lipid Chromatography with mass detection (UHPLC-MS/MS) connected to newestgeneration of quadrupole time of flight mass detector (Q-TOF) with source of ions type electro-spray (ESI) orchemical ionization under atmospheric pressure (APCI).High Performance Lipid Chromatography (HPLC) with detection: RID, FL and UV-DAD.Infrared spectroscopy with Fourier Transformation (IR).Spectroscopy UV-VIS. Detectors:Overview of Analytical Equipment: micrOTOF-Q-II - BrukerSpectrometer UV-VIS – Jasco RID – ShodexSpectrometer IR- Jasco FL-MerckHPLC-Merck UV-DAD - DionexUHPLC-Dionex FID- Perkin ElmerPLC- Dionex ECD-Perkin ElmerGC-Perkin- Elmer NPD- Perkin Elmer MS/MS - Bruker 10
  • Synthesis department BLIRT – Synthesis services We offer all-embracing organic synthesis services directed to industrial and scientific customers:  Pharmaceutical Industry;  Chemical Industry;  Academic Scientists; In particular we specialize in synthesis:  chiral compounds with natural origin – with synthetic and bio-catalytic methods;  chiral unnatural/non-peptidic amino acids;  peptides (‘on solid state’ and ‘in solution’);  heterocyclic compounds (with N, O, S in ring structure);  macrocyclic compounds;  phosphoroorganic compounds; www.blirt.eu 11
  • Synthesis departmentWe offer comprehensive organic synthesis and interdisciplinary chemistryservices:  Custom synthesis - comprehensive equiped laboratory: mg – 100s g scale;  Design of alternative synthetic pathways;  Optimalization of synthetic routes;  Reaction yields optimalization;  Identification, synthesis and standarization of API impurities;  Identification, synthesis and standarization of drug metabolites; COOMe O OH CHO A B CH3 CH3 Br COOMe COOMe F CH3 F F C OH CH3 E D CH3 CH3 O CN COOH O COOH F www.blirt.eu
  • Collaboration models  Fee for Service  Co-development  FTE  Consulting www.blirt.eu 13
  • Summary Key benefits of collaboration • Competitive pricing • Short project deadlines • Strong scientific team • State of the art facilities  Service Quality • ISO 9001:2009 - certificate • GLP - pending.- 03.2011 • GMP – planned for 2013 14